• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIDRAdisk:评估化脓性汗腺炎负担的创新视觉工具的验证。

HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa.

机构信息

Istituto di Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma - Università Cattolica del Sacro Cuore, Rome, Italy.

Unità di Dermatologia, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.

出版信息

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):766-773. doi: 10.1111/jdv.15425. Epub 2019 Mar 5.

DOI:10.1111/jdv.15425
PMID:30633405
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6593467/
Abstract

BACKGROUND

Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disease characterized by painful inflamed nodules, recurrent abscesses and fistulas located in apocrine gland-bearing body sites. The negative impact of HS on patient's quality of life (QoL) has been reported to be greater than other dermatologic conditions as psoriasis and atopic eczema, and its improvement is an important goal in disease management. Nowadays, there are no specific validated QoL instruments available for HS and generic dermatologic questionnaires are used.

OBJECTIVE

The objective of this study was to demonstrate the validity, reliability and responsiveness of HIDRAdisk, a new innovative tool designed for rapid assessment of HS burden and, at the same time, an intuitive graphic visualization of the measurement outcome.

METHODS

A multicentre, longitudinal, observational study was conducted to validate the HIDRAdisk compared with other validated questionnaires [Skindex-16, Dermatology Life Quality Index (DLQI), Work Productivity and Activity Impairment-General Health (WPAI:GH)] and to evaluate its correlation with disease severity in Italian patients with any degree of HS severity, as measured by Hurley stage and HS Physician Global Assessment (HS-PGA).

RESULTS

A total of 140 patients (59% women; mean age 34.9 ± 11.0 years) were enrolled in 27 dermatologic centres. HIDRAdisk showed a strong correlation with Skindex-16 and DLQI, and a good one with WPAI:GH (correlation coefficient: 0.7568, 0.6651 and 0.5947, respectively) and a statistically significant correlation with both Hurley stage and HS-PGA. Very good internal consistency (Cronbach coefficient >0.80; intraclass correlation coefficient >0.6), with correlation between the 10 items, good test-retest reliability (Spearman correlation coefficient, 0.8331; P < 0.0001) and responsiveness to changes were demonstrated.

CONCLUSION

Our study shows that HIDRAdisk, a short and innovative visual HS QoL instrument, has been psychometrically validated in Italian language and it may help improve the management of HS once implemented in routine clinical practice.

摘要

背景

化脓性汗腺炎(HS)是一种慢性、复发性、炎症性皮肤病,其特征为疼痛性炎症性结节、反复发作的脓肿和位于顶泌腺部位的瘘管。与银屑病和特应性皮炎等其他皮肤病相比,HS 对患者生活质量(QoL)的负面影响更大,改善 HS 是疾病管理的重要目标。目前,尚无专门针对 HS 的经过验证的 QoL 工具,而是使用通用的皮肤科问卷。

目的

本研究旨在证明 HIDRAdisk 的有效性、可靠性和反应性,HIDRAdisk 是一种新的创新工具,用于快速评估 HS 负担,同时直观地显示测量结果。

方法

进行了一项多中心、纵向、观察性研究,以验证 HIDRAdisk 与其他经过验证的问卷(Skindex-16、皮肤病生活质量指数(DLQI)、工作效率和活动障碍-一般健康(WPAI:GH))的相关性,并评估其与意大利任何严重程度 HS 患者(根据 Hurley 分期和 HS 医生整体评估(HS-PGA))疾病严重程度的相关性。

结果

共纳入 140 例患者(59%为女性;平均年龄 34.9±11.0 岁),来自 27 个皮肤科中心。HIDRAdisk 与 Skindex-16 和 DLQI 具有很强的相关性,与 WPAI:GH 也具有良好的相关性(相关系数分别为 0.7568、0.6651 和 0.5947),与 Hurley 分期和 HS-PGA 也具有统计学显著相关性。HIDRAdisk 具有非常好的内部一致性(Cronbach 系数>0.80;组内相关系数>0.6),10 个项目之间具有相关性,具有良好的重测信度(Spearman 相关系数,0.8331;P<0.0001)和对变化的反应能力。

结论

我们的研究表明,HIDRAdisk 是一种简短而创新的视觉 HS QoL 工具,已在意大利语中进行了心理测量学验证,一旦在常规临床实践中实施,它可能有助于改善 HS 的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c500/6593467/88c6e467cda0/JDV-33-766-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c500/6593467/724e0f5ec640/JDV-33-766-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c500/6593467/77bae756c83f/JDV-33-766-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c500/6593467/88c6e467cda0/JDV-33-766-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c500/6593467/724e0f5ec640/JDV-33-766-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c500/6593467/77bae756c83f/JDV-33-766-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c500/6593467/88c6e467cda0/JDV-33-766-g003.jpg

相似文献

1
HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa.HIDRAdisk:评估化脓性汗腺炎负担的创新视觉工具的验证。
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):766-773. doi: 10.1111/jdv.15425. Epub 2019 Mar 5.
2
Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of Disease.意大利大样本人群的化脓性汗腺炎:疾病负担评估。
Dermatology. 2022;238(3):487-497. doi: 10.1159/000517412. Epub 2021 Sep 2.
3
Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients.年龄和性别对阿达木单抗治疗化脓性汗腺炎患者 HIDRAdisk 结局的影响。
J Eur Acad Dermatol Venereol. 2019 Oct;33 Suppl 6:25-27. doi: 10.1111/jdv.15821.
4
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。
Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.
5
Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.化脓性汗腺炎临床反应在化脓性汗腺炎患者评估中的可靠性
J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2254-2256. doi: 10.1111/jdv.15163. Epub 2018 Jul 17.
6
Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa.EQ-5D-5L、Skindex-16、DLQI和DLQI-R在化脓性汗腺炎患者中的效度。
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2584-2592. doi: 10.1111/jdv.16642. Epub 2020 Jul 2.
7
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.评估化脓性汗腺炎临床应答(HiSCR)作为化脓性汗腺炎治疗的临床终点的有效性、反应性和有意义性。
Br J Dermatol. 2014 Dec;171(6):1434-42. doi: 10.1111/bjd.13270. Epub 2014 Nov 11.
8
Assessing the psychological burden of patients with hidradenitis suppurativa.评估化脓性汗腺炎患者的心理负担。
Eur J Dermatol. 2019 Jun 1;29(3):294-301. doi: 10.1684/ejd.2019.3552.
9
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa.AISI:一种用于化脓性汗腺炎的新疾病严重程度评估工具。
Wounds. 2015 Oct;27(10):258-64.
10
Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment.化脓性汗腺炎改良 Hurley 分级与患者报告的生活质量和客观疾病严重程度评估的相关性。
Br J Dermatol. 2019 May;180(5):1214-1220. doi: 10.1111/bjd.17508. Epub 2019 Feb 25.

引用本文的文献

1
The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality-of-life instruments: A systematic review.皮肤病生活质量指数(DLQI)用作101种生活质量工具验证的基准:一项系统评价。
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):631-679. doi: 10.1111/jdv.20321. Epub 2024 Sep 13.
2
Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel.如何将手术与生物制剂靶向治疗相结合治疗化脓性汗腺炎的指南:来自意大利专家小组的德尔菲共识声明
Dermatology. 2024;240(5-6):885-896. doi: 10.1159/000539264. Epub 2024 Jul 18.
3

本文引用的文献

1
HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa.HIDRAdisk:一种评估化脓性汗腺炎负担的创新视觉工具。
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):e24-e26. doi: 10.1111/jdv.15122. Epub 2018 Jun 27.
2
A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa.一种用于化脓性汗腺炎的新型严重程度评估评分系统。
JAMA Dermatol. 2018 Mar 1;154(3):330-335. doi: 10.1001/jamadermatol.2017.5890.
3
Hidradenitis suppurativa burden of disease tool: Pilot testing of a disease-specific quality of life questionnaire.
Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes.
化脓性汗腺炎的负担:患者报告结局的系统文献综述
Dermatol Ther (Heidelb). 2024 Jan;14(1):83-98. doi: 10.1007/s13555-023-01085-w. Epub 2024 Jan 6.
4
Trends in Hidradenitis Suppurativa Disease Severity and Quality of Life Outcome Measures: Scoping Review.化脓性汗腺炎疾病严重程度及生活质量结局指标的趋势:范围综述
JMIR Dermatol. 2021 Oct 1;4(2):e27869. doi: 10.2196/27869.
5
Quality of life in Hidradenitis Suppurativa (Acne Inversa): A scoping review.化脓性汗腺炎(反向性痤疮)的生活质量:一项范围综述。
Skin Health Dis. 2023 Feb 21;3(4):e214. doi: 10.1002/ski2.214. eCollection 2023 Aug.
6
Assessing unmet needs in patients with hidradenitis suppurativa.评估化脓性汗腺炎患者的未满足需求。
Arch Dermatol Res. 2023 Nov;315(9):2555-2560. doi: 10.1007/s00403-023-02645-y. Epub 2023 Jun 1.
7
Supporting employers and their employees with Mental hEalth problems to remain eNgaged and producTive at wORk (MENTOR): A feasibility randomised controlled trial protocol.支持有心理健康问题的雇主及其员工在工作中保持投入和高效(MENTOR):一项可行性随机对照试验方案。
PLoS One. 2023 Apr 20;18(4):e0283598. doi: 10.1371/journal.pone.0283598. eCollection 2023.
8
SCI-QOL and WOUND-Q Have the Best Patient-reported Outcome Measure Design: A Systematic Literature Review of PROMs Used in Chronic Wounds.SCI-QOL和WOUND-Q具有最佳的患者报告结局测量设计:慢性伤口中使用的患者报告结局测量指标的系统文献综述
Plast Reconstr Surg Glob Open. 2023 Jan 10;11(1):e4723. doi: 10.1097/GOX.0000000000004723. eCollection 2023 Jan.
9
Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments.全身性治疗的化脓性汗腺炎患者的肿瘤学意义
Biomedicines. 2021 Nov 1;9(11):1594. doi: 10.3390/biomedicines9111594.
10
Development of a visual tool to assess six dimensions of health and its validation in patients with endocrine disorders.开发一种评估健康六个维度的视觉工具及其在内分泌疾病患者中的验证。
Wien Klin Wochenschr. 2022 Aug;134(15-16):569-580. doi: 10.1007/s00508-021-01809-y. Epub 2021 Feb 4.
化脓性汗腺炎疾病负担工具:一种疾病特异性生活质量问卷的初步测试
J Am Acad Dermatol. 2018 Jan;78(1):215-217.e2. doi: 10.1016/j.jaad.2017.08.030.
4
Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa.用于评估化脓性汗腺炎症状及影响的患者报告结局问卷的开发与初步心理测量学评估
J Dermatolog Treat. 2018 Mar;29(2):152-164. doi: 10.1080/09546634.2017.1341614. Epub 2017 Jul 4.
5
Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study.化脓性汗腺炎患者的生活质量损害:一项加拿大的研究。
Am J Clin Dermatol. 2015 Feb;16(1):61-5. doi: 10.1007/s40257-014-0105-5.
6
Results of the validation study of the Psodisk instrument, and determination of the cut-off scores for varying degrees of impairment.Psodisk仪器的验证研究结果以及不同程度损伤的临界值确定。
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):725-31. doi: 10.1111/jdv.12668. Epub 2014 Sep 17.
7
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.评估化脓性汗腺炎临床应答(HiSCR)作为化脓性汗腺炎治疗的临床终点的有效性、反应性和有意义性。
Br J Dermatol. 2014 Dec;171(6):1434-42. doi: 10.1111/bjd.13270. Epub 2014 Nov 11.
8
Enhancing patient-centered communication and collaboration by using the electronic health record in the examination room.通过在检查室使用电子健康记录来加强以患者为中心的沟通与协作。
JAMA. 2013 Jun 12;309(22):2327-8. doi: 10.1001/jama.2013.6030.
9
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.阿达木单抗治疗中重度化脓性汗腺炎的平行随机试验。
Ann Intern Med. 2012 Dec 18;157(12):846-55. doi: 10.7326/0003-4819-157-12-201212180-00004.
10
Depression in patients with hidradenitis suppurativa.化脓性汗腺炎患者的抑郁。
J Eur Acad Dermatol Venereol. 2013 Apr;27(4):473-8. doi: 10.1111/j.1468-3083.2012.04468.x. Epub 2012 Feb 20.